ReviewCancer metastasis reviews2013
Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic.
Review in Cancer metastasis reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- The mouse prostate: a basic anatomical and histological guideline.Bosnian journal of basic medical sciences · 2016Guideline
- Neuromedin U 'innervation' reprograms myeloid immunosuppression in neuroendocrine prostate cancer.Oncogene · 2026Article
- Molecular Iodine Induces Anti- and Pro-Neoplastic Effects in Prostate Cancer Models.International journal of molecular sciences · 2025Article
- Diverse landscape of genetically engineered mouse models: Genomic and molecular insights into prostate cancer.Cancer letters · 2024Review
- Orchestration of miRNA Patterns by Testosterone and Dietary Tomato Carotenoids during Early Prostate Carcinogenesis in TRAMP Mice.The Journal of nutrition · 2023Article
- Article
- The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, decreases DNA damage repair, and predicts therapy responses.Research square · 2023Article
- Prostate Cancer Secretome and Membrane Proteome fromInternational journal of molecular sciences · 2022Article
- Tomatoes, Lycopene, and Prostate Cancer: What Have We Learned from Experimental Models?The Journal of nutrition · 2022Review
- ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3β dependent Nkx3.1 degradation.Cancer letters · 2022Article
- Alzheimer's Disease, and Breast and Prostate Cancer Research: Translational Failures and the Importance to Monitor Outputs and Impact of Funded Research.Animals : an open access journal from MDPI · 2020Review
- Proscillaridin A slows the prostate cancer progression through triggering the activation of endoplasmic reticulum stress.Cell cycle (Georgetown, Tex.) · 2020Article
- The PHLPP2 phosphatase is a druggable driver of prostate cancer progression.The Journal of cell biology · 2019Article
- Research Evidence on High-Fat Diet-Induced Prostate Cancer Development and Progression.Journal of clinical medicine · 2019Review
- Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic Era.Cold Spring Harbor perspectives in medicine · 2019Review
- Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate.The Prostate · 2018Article
- Preclinical and Coclinical Studies in Prostate Cancer.Cold Spring Harbor perspectives in medicine · 2018Review
- Identification of potential therapeutic targets in prostate cancer through a cross-species approach.EMBO molecular medicine · 2018Article
- Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKɛ/TBK1/NF-κB signaling.Theranostics · 2018Article
- Estrogens and Their Receptors in Prostate Cancer: Therapeutic Implications.Frontiers in oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
More than 15 years ago, the first generation of genetically engineered mouse (GEM) models of prostate cancer was introduced. These transgenic models utilized prostate-specific promoters to express SV40 oncogenes specifically in prostate epithelium. Since the description of these initial models, there have been a plethora of GEM models of prostate cancer representing various perturbations of oncogenes or tumor suppressors, either alone or in combination. This review describes these GEM models, focusing on their relevance for human prostate cancer and highlighting their strengths and limitations, as well as opportunities for the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.